NET

Festool Unveils New Drywall Sander for the Modern Professional: Setting New Standard for the Drywall Sanding Experience

Retrieved on: 
Thursday, February 15, 2024

LEBANON, Ind., Feb. 15, 2024 /PRNewswire/ -- Festool, a leading manufacturer of innovative, precision-engineered, and durable power tool solutions, today announced new sanding and abrasive solutions for drywallers and painters, along with a new guide rail set designed to meet the needs of woodworkers. Available beginning March 15, 2024, the PLANEX LHS 2-M Drywall Sander (PLANEX M), two abrasive combo kits, and FS 1400/2-KP Guide Rail Starter Set are designed to enhance efficiency and improve finish results on the jobsite and in the shop.

Key Points: 
  • PLANEX LHS 2-M Drywall Sander: The Specialist for Smooth Walls & Ceilings
    The Planex M redefines the sanding pattern with its easy-to-use interface.
  • The ergonomic design is highly controllable and comfortable while being able to reach most surfaces.
  • With a working length of 55-inches and an ergonomic T-shaped handle, it is comfortable to handle and well-suited for standard room height.
  • Starting March 15, 2024, the PLANEX LHS 2-M Drywall Sander (577359) will be available starting at $999.00.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

Curasight announces acceleration of therapeutic strategy to strengthen position as a radiopharmaceutical theranostic company

Retrieved on: 
Tuesday, February 13, 2024

COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.

Key Points: 
  • COPENHAGEN, Denmark, Feb. 13, 2024 /PRNewswire/ -- Curasight A/S ("Curasight" or the "Company" (XSAT: CURAS) announces today that it is accelerating and expanding its clinical therapeutic strategy with the addition of a new Phase I/IIa trial to include a total of five cancer indications in a so called basket trial design.
  • To strengthen the Company's capital structure and secure funding for the acceleration of clinical activities, Curasight intends to launch a rights issue during the first quarter of 2024.
  • By launching this basket trial, we can accelerate development of both uTRACE and uTREAT (theranostic) in parallel and potentially have therapeutic efficacy data already during 2025.
  • Under the terms of the deal, Curasight is responsible for development until regulatory approval with Curium responsible for manufacturing and commercialisation.

ABVC BioPharma Receives Australian Patent, Valid Until 2040, for Its Treatment of Major Depressive Disorder (MDD)

Retrieved on: 
Monday, February 12, 2024

2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).

Key Points: 
  • 2021314052, for the use of PDC-1421, a Radix Polygala (Polygala tenuifolia Willd) extract, used in the Company's asset ABV-1504 for the treatment of Major Depressive Disorder (MDD).
  • The Company was previously awarded a U.S. patent, US 11,554,154 B2, on April 25, 2023, for the same treatment.
  • The patent application was submitted to the Australian Patent and Trademark Office under "Polygala Extract for the Treatment of Major Depressive Disorder."
  • The invention relates to oral administration of the formulation containing a Radix Polygala (Polygala tenuifolia Willd) extract, PDC-1421, as a capsule for treating Major Depressive Disorder.

NEVADA KING INTERCEPTS 3.52 G/T AU OVER 61.0M AND 6.05 G/T AU OVER 41.1M INCLUDING 19.44 G/T AU OVER 7.6M, EXTENDS OXIDE MINERALIZATION 300M NORTHWEST OF THE ATLANTA PIT

Retrieved on: 
Monday, February 12, 2024

AT23WS-62 intercepted 6.05 g/t Au over 41.1m including 19.44 g/t Au over 7.6m and was drilled approximately 300m northwest of the Atlanta Pit approximately 8m west of historical RC hole DHRI-12-MRC1 (1.95g/t Au over 77.8m), which did not completely penetrate the mineralized zone.

Key Points: 
  • AT23WS-62 intercepted 6.05 g/t Au over 41.1m including 19.44 g/t Au over 7.6m and was drilled approximately 300m northwest of the Atlanta Pit approximately 8m west of historical RC hole DHRI-12-MRC1 (1.95g/t Au over 77.8m), which did not completely penetrate the mineralized zone.
  • AT23WS-62 did fully penetrate the mineralized zone and returned an average grade three times greater than DHRI-12-MRC1.
  • Referring to Figure 2, AT23WS-62 drilled across a high-angle structure into an adjacent mineralized block, which accounts for the shorter intercept length when compared to DHRI-12-MRC1.
  • As we continue testing for similar mineralization along lines north and south of Section 22-16N(2), good potential exists for building tonnage.

Thinking about trading options or stock in Cloudflare, Walt Disney, Ford Motor, Synopsys, or Marathon Digital?

Retrieved on: 
Friday, February 9, 2024

NEW YORK, Feb. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NET, DIS, F, SNPS, and MARA.

Key Points: 
  • NEW YORK, Feb. 9, 2024 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NET, DIS, F, SNPS, and MARA.
  • Click a link below then choose between in-depth options trade idea report or a stock score report.
  • Options Report – Ideal trade ideas on up to seven different options trading strategies.
  • The report shows all vital aspects of each option trade idea for each stock.

Exelixis Announces Fourth Quarter and Fiscal Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Tuesday, February 6, 2024

In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.

Key Points: 
  • In 2023, global cabozantinib franchise net product revenues generated by Exelixis and its partners exceeded $2.2 billion.
  • Based upon cabozantinib-related net product revenues generated by Exelixis’ collaboration partners during the quarter and year ended December 31, 2023, Exelixis earned $40.7 million and $148.5 million, respectively, in royalty revenues.
  • In October 2023, detailed results were presented from the phase 3 CABINET pivotal trial at the 2023 ESMO Congress.
  • Exelixis management will discuss the company’s financial results for the fourth quarter and fiscal year of 2023 and provide a general business update during a conference call beginning at 5:00 p.m.

Levi & Korsinsky, LLP Announces a Proposed Settlement in the Corcept Therapeutics Incorporated Securities Litigation

Retrieved on: 
Monday, February 5, 2024

YOUR RIGHTS MAY BE AFFECTED BY THE PROPOSED SETTLEMENT OF A CLASS ACTION LAWSUIT PENDING IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA (THE "COURT").

Key Points: 
  • YOUR RIGHTS MAY BE AFFECTED BY THE PROPOSED SETTLEMENT OF A CLASS ACTION LAWSUIT PENDING IN THE UNITED STATES DISTRICT COURT FOR THE NORTHERN DISTRICT OF CALIFORNIA (THE "COURT").
  • PLEASE DO NOT CONTACT THE COURT, CORCEPT THERAPEUTICS INCORPORATED, OR ANY OTHER DEFENDANT, OR THEIR COUNSEL, REGARDING THIS NOTICE.
  • ALL QUESTIONS ABOUT THIS NOTICE, THE PROPOSED SETTLEMENT, OR YOUR ELIGIBILITY TO PARTICIPATE IN THE PROPOSED SETTLEMENT SHOULD BE DIRECTED TO LEAD COUNSEL OR THE CLAIMS ADMINISTRATOR, WHOSE CONTACT INFORMATION IS PROVIDED BELOW.
  • IF YOU ARE A MEMBER OF THE SETTLEMENT CLASS, YOUR RIGHTS MAY BE AFFECTED BY THE PROPOSED SETTLEMENT AND YOU MAY BE ENTITLED TO SHARE IN THE NET SETTLEMENT FUND.

O`KEY GROUP REPORTS 5.2% NET RETAIL REVENUE GROWTH, DA! DISCOUNTERS REVENUE GREW 22.1% IN Q4 2023

Retrieved on: 
Monday, February 5, 2024

Group net retail revenue [1] grew by 5.2% YoY to RUB 58.5 bn, driven by positive LFL performance of both O’KEY and DA!

Key Points: 
  • Group net retail revenue [1] grew by 5.2% YoY to RUB 58.5 bn, driven by positive LFL performance of both O’KEY and DA!
  • discounters' net retail revenue increased by 22.1% YoY to RUB 17.5 bn, led by both LFL net retail revenue growth and the chain’s expansion.
  • O`KEY hypermarkets’ net retail revenue decreased by 3.4% YoY to RUB 141.9 bn due to a decrease in LFL revenue and selling space.
  • discounters’ net retail revenue grew by 19.8% YoY to RUB 63.8 bn, led by LFL revenue and selling space growth.

InventHelp Inventor Develops New Mobile Software Application for Truck Drivers (CPC-739)

Retrieved on: 
Wednesday, January 31, 2024

In doing so, it assists drivers with finding return loads in either local or long-haul cargo delivery service environments.

Key Points: 
  • In doing so, it assists drivers with finding return loads in either local or long-haul cargo delivery service environments.
  • As a result, it increases efficiency and it could allow for better and more affordable service to customers.
  • The invention features an effective design that is easy to use so it is ideal for the trucking industry and business owners.
  • 22-CPC-739, InventHelp, 100 Beecham Drive, Suite 110, Pittsburgh, PA 15205-9801, or call (412) 288-1300 ext.